Szarek M, et al. - In this pre-specified analysis, researchers tested the magnitude of alirocumab’s efficacy in attenuating total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in the ODYSSEY OUTCOMES trial, wherein 18,924 patients with acute coronary syndrome (ACS) received alirocumab or placebo, added to high-intensity or maximum-tolerated statin treatment, and alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. With alirocumab compared with placebo, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed, with 3,064 first and 5,425 total events. The investigators noted that alirocumab-prevented total number of nonfatal cardiovascular events and deaths were twice the number of first events prevented in patients with ACS. Total event reduction affords a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.